Compare MSC & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MSC | LBRX |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 607.6M | 563.2M |
| IPO Year | 2018 | 2025 |
| Metric | MSC | LBRX |
|---|---|---|
| Price | $3.01 | $21.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $49.00 |
| AVG Volume (30 Days) | 2.1K | ★ 191.8K |
| Earning Date | 02-26-2026 | 06-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $687,148,000.00 | N/A |
| Revenue This Year | $8.92 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 9.50 | N/A |
| 52 Week Low | $2.30 | $13.36 |
| 52 Week High | $6.63 | $24.46 |
| Indicator | MSC | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 41.45 | 49.41 |
| Support Level | $2.99 | $20.46 |
| Resistance Level | $3.12 | $23.50 |
| Average True Range (ATR) | 0.16 | 1.97 |
| MACD | -0.03 | -0.11 |
| Stochastic Oscillator | 2.41 | 39.53 |
Studio City International Holdings Ltd is a gaming, retail, and entertainment resort located in Cotai, Macau. It operates Studio City Casino with around 250 mass-market gaming tables; including tables for VIP rolling chip operations, and 552 gaming machines. Studio City features luxury hotel rooms, diverse food and beverage establishments, and complementary retail space. In addition, the company offers non-gaming attractions, including the world's first figure-8 Ferris wheel, a deluxe nightclub and karaoke venue, a live performance arena, an outdoor and an indoor water park. Geographically, the company derives the majority of its revenue from the Macau region.
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.